English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Disseminated intravascular coagulation (DIC) is a systemic condition secondary to an underlying process that affects hemostasis, causing thrombocytopenia and coagulation factor consumption. Severe sepsis, polytraumatic lesions, obstetric complications, cancer, and acute promyelocytic leukemia are, some of the pathologies that can trigger this hemostatic disorder. Despite the severity of DIC, there have been minimal changes in the therapeutic approach over time. The cornerstone of treatment is to identify the etiology and eliminate the underlying cause. On the other hand, it is necessary to replace the lack of blood elements such as platelets and coagulation factors, using fresh frozen plasma or clotting factor concentrates. In this paper, we have reviewed the timeline over 30 years regarding the evolution of therapeutic hematologic support for DIC.

Hematologist Intervention in Disseminated Intravascular Coagulation - Has Something Changed in 2018?